ReviewPharmaceuticals (Basel, Switzerland)2023
A Review of Recent Pharmacological Advances in the Management of Diabetes-Associated Peripheral Neuropathy.
Review in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 16 citations in OpenAlex.
- Spinal Cord Stimulation for Painful Diabetic Neuropathy: A Systematic Review and Meta-Analysis of High- and Low-Frequency Modalities.Pain research & management · 2026Pooled it
- Exploring the efficacy of plant-based nutraceuticals in managing diabetic neuropathy.Inflammopharmacology · 2025Pooled it
- E-52862-A selective sigma-1 receptor antagonist, in peripheral neuropathic pain: Two randomized, double-blind, phase 2 studies in patients with chronic postsurgical pain and painful diabetic neuropathy.European journal of pain (London, England) · 2025Trial
- Vitamin B Supplementation for Diabetic Peripheral Neuropathy: A Review and Meta-Analysis.Journal of clinical medicine · 2026Review
- L-Serine Attenuates Metabolic and Behavioural Features of Diabetic Neuropathy with Dose-Dependent Central Proteomic Correlates in a Rat Model.Biomolecules · 2026Article
- The Potential Indirect Impact of GLP-1 Receptor Agonists in the Management of Fibromyalgia.Journal of clinical medicine · 2026Review
- Diabetic Peripheral Neuropathy: New Diagnostics and Treatment Perspectives.Drugs & aging · 2026Review
- Applications of Tailored Mesoporous Silicate Nanomaterials in Regenerative Medicine and Theranostics.International journal of molecular sciences · 2025Review
- Assessment for Diabetic Neuropathy: Treatment and Neurobiological Perspective.Current diabetes reviews · 2025Review
- Evaluating the Content Validity of the Modified Neuropathy Total Symptom Score-6 Self-Administered (mNTSS-6-SA) in a Painful Diabetic Peripheral Neuropathy Population.Journal of pain research · 2025Article
- A Conceptual Model of Patient Experiences of Painful Diabetic Peripheral Neuropathy to Support Clinical Outcomes Assessment.Journal of pain research · 2025Article
- The Role of Phytochemicals in Managing Neuropathic Pain: How Much Progress Have We Made?Nutrients · 2024Review
- Recent Advances in Biomolecular Patho-Mechanistic Pathways behind the Development and Progression of Diabetic Neuropathy.Biomedicines · 2024Review
- Article
- Sodium-Glucose Cotransporter 2 Inhibitors and Reduced Fibromyalgia Risk in Patients With Diabetes: A Target Trial Emulation Study.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic peripheral neuropathy is a common complication of longstanding diabetes mellitus. These neuropathies can present in various forms, and with the increasing prevalence of diabetes mellitus, a subsequent increase in peripheral neuropathy cases has been noted. Peripheral neuropathy has a significant societal and economic burden, with patients requiring concomitant medication and often experiencing a decline in their quality of life. There is currently a wide variety of pharmacological interventions, including serotonin norepinephrine reuptake inhibitors, gapentanoids, sodium channel blockers, and tricyclic antidepressants. These medications will be discussed, as well as their respective efficacies. Recent advances in the treatment of diabetes mellitus with incretin system-modulating drugs, specifically glucagon-like peptide-1 agonists, have been promising, and their potential implication in the treatment of peripheral diabetic neuropathy is discussed in this review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.